ESH MDS 2024 | The standards for managing anemia in patients with MDS
Eva Hellström-Lindberg, MD, PhD, Karolinska University Hospital Huddinge, Stockholm, Sweden, briefly discusses the prognostic relevance of anemia in patients with myelodysplastic syndromes (MDS). When considering anemia, neutropenia, and thrombocytopenia, the evidence suggests that anemia is the strongest predictor of poor survival in MDS. Alongside the Molecular International Prognostic Scoring System (IPSS-M), transfusion dependency is an independent risk factor. Prof. Hellström-Lindberg suggests a novel therapeutic strategy is needed that aims to initiate anemia treatment prior to the onset of transfusion dependency in patients. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
